Medtronic Raises 2027 Outlook Amid Surge in Heart Device Demand

Medtronic has revised its fiscal 2027 financial outlook upwards, buoyed by strong demand for its heart devices used in complex cardiovascular procedures. The company announced the updated forecasts on Tuesday, reflecting increased confidence in its growth trajectory.

Strong Financial Projections

The medical technology company raised the lower end of its adjusted per-share profit forecast for fiscal 2027 from $5.90 to $5.94, maintaining the upper limit at $6. Additionally, Medtronic now anticipates annual organic revenue growth between 7.25% and 7.75%, an increase from the previously projected range of 6.75% to 7.25%.

CEO Geoff Martha highlighted the broad performance across the company's businesses and contributions from new growth platforms as key drivers for the optimistic outlook. "The breadth of our performance and the increasing contributions from our newer growth platforms give us confidence," Martha stated during a post-earnings call.

Strategic Investments and Expansions

Further bolstering its position in the medical devices sector, Medtronic has committed $80 million to heart-valve repair device maker Pi-Cardia, with an option to acquire the company for $210 million. In a separate move, Medtronic invested $700 million in Cornerstone Robotics, securing distribution rights for a robotic surgical device in select markets outside the United States. Martha noted the low penetration of soft tissue robotic surgery in emerging markets, indicating significant growth potential.

"We've maintained a steady cadence of mergers and acquisitions, focusing on high-growth segments within medtech that are backed by large patient pools," Martha remarked.

Cardiovascular Segment Growth

Medtronic's cardiovascular segment reported a notable 19.5% increase in quarterly sales, reaching $3.93 billion. This growth was largely driven by the company's pulsed field ablation portfolio, which saw a staggering 88% rise. The portfolio is instrumental in treating irregular heart rhythms, contributing significantly to the segment's strong performance.

For the quarter, Medtronic posted an adjusted per-share profit of $1.45 on revenue of $9.76 billion, surpassing analysts' expectations of $1.39 per share on $9.55 billion in revenue, according to LSEG-compiled data.

Despite receiving tariff refunds that nearly covered the duties paid during the quarter, Medtronic's CFO Thierry Pieton clarified that these potential future refunds are not factored into the current financial outlook.